A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers.

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of different dose levels of PRV-002 in Health Volunteers

Study Overview

• Status: Completed
• Conditions: Traumatic Brain Injury (TBI)
• Intervention / Treatment: Drug: Placebo; Drug: PRV-002

Detailed Description

This Phase 1 study is designed to assess the safety, tolerabilty and pharmcokinetics of different dose levels of PRV-002 in Healthy Volunteers. The study will evaluate 3 dose levels of the investigational product, PRV-002, in 5 cohorts of 8 healthy volunteers per cohort. In each cohort, 6 volunteers will receive the investigational product and 2 volunteers will receive placebo. Dose levels will be evaluated in a sequential manner starting at the lowest dose level. Cohorts 1 - 3 will receive a single dose of PRV-002 or placebo. Cohorts will receive one dose of PRV-002 or placebo per day for 5 consecutive days.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • Melbourne, Victoria, Australia, 3004
      • Nucleus Network Pty Ltd,

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
2. Adult males and females, 18 to 55 years of age (inclusive) at screening.
3. Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2, with a body weight (to 1 decimal place) ≥ 50 kg at screening.
4. Be non-smokers (including tobacco, e-cigarettes and marijuana) for at least 3 months prior to first study drug administration.
5. Have a negative test for cotinine at the screening visit and at check-in on Day -1.

6. Medically healthy without clinically significant abnormalities (in the opinion of the Investigator) at the screening visit in the Schedules of

   Assessments (SoA), including:

   1. Physical examination without any clinically significant findings
   2. Systolic BP in the range of 90 to 160 mmHg (inclusive) and diastolic BP in the range of 50 to 95 mmHg (inclusive) after 5 minutes in supine position
   3. Heart rate in the range of 40 to 100 bpm (inclusive) after 5 minutes rest in supine position
   4. Body temperature (tympanic or oral) in the range 35.5°C to 37.7°C (inclusive)
   5. No clinically significant findings in serum chemistry, haematology, coagulation, and urinalysis tests
   6. Triplicate 12-lead ECG (taken after the volunteer has been supine for at least 5 minutes) with a QTcF ≤ 450 msec for males and ≤ 470 msec for females and no clinically significant abnormalities
   7. Pulmonary assessments must be within the normal range (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC] and FEV1/FVC ratio ≥ 80% of normal values; f forced expiratory flow over the middle one half of the FVC [FEF25-75%] > 75% of predicted)
   8. Oxygen saturation (SpO2) monitor ≥ 95%.

7. Medically healthy without clinically significant abnormalities (in the opinion of the Investigator) at the timepoints indicated in the Schedules of Assessments (SoA), including:

   1. Physical examination without any clinically significant findings
   2. Systolic BP in the range of 90 to 160 mmHg (inclusive) and diastolic BP in the range of 50 to 95 mmHg (inclusive) after 5 minutes in supine position
   3. Heart rate in the range of 40 to 100 bpm (inclusive) after 5 minutes rest in supine position
   4. Body temperature (tympanic or oral) in the range 35.5°C to 37.7°C (inclusive)
   5. No clinically significant findings in serum chemistry, haematology, coagulation, and urinalysis tests
   6. Triplicate 12-lead ECG (taken after the volunteer has been supine for at least 5 minutes) with a QTcF ≤ 450 msec for males and ≤ 470 msec for females and no clinically significant abnormalities
   7. Pulmonary assessments must be within the normal range (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC] and FEV1/FVC ratio ≥ 80% of normal values; f forced expiratory flow over the middle one half of the FVC [FEF25-75%] > 75% of predicted)
   8. Oxygen saturation (SpO2) monitor ≥ 95%.

8. Female volunteers must:

   1. Be of nonchildbearing potential i.e., surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before screening) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause
   2. Have a follicle-stimulating hormone level >40 IU/L at the screening visit),or
   3. If of childbearing potential, must agree not to donate ova, not to attempt to become pregnant and, if engaging in sexual intercourse with a male partner, must agree to use an acceptable method of contraception from signing the consent form until at least 30 days after the last dose of the study drug.
9. Male volunteers must agree not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must agree to use an acceptable method of contraception from signing the consent form until at least 90 days after the last dose of study drug.
10. Have suitable venous access for blood sampling.

11. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

    -

Exclusion Criteria:

1. History or presence of significant cardiovascular disease
2. History or presence of significant pulmonary disease
3. History or presence of significant hepatic disease
4. History or presence of significant renal disease
5. History or presence of significant haematological disease
6. History or presence of significant gastrointestinal disease
7. History or presence of significant disease
8. History or presence of significant endocrine disease
9. History or presence of significant immunologic disease
10. History or presence of significant dermatologic disease
11. History or presence of significant or neurological disease
12. No major surgery within the past 3 months determined by the PI to be clinically significant.
13. Absence of any acute illness.
14. Current infection that requires systemically absorbed antibiotic.
15. Current infection that requires systemically absorbed antifungal.
16. Current infection that requires systemically absorbed antiparasitic.
17. Current infection that requires systemically absorbed antiviral medication.
18. Any history of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma).
19. Presence of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.
20. Use of or plans to use systemic immunosuppressive (e.g., corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) during the study or within 3 months prior to the first study drug administration.
21. History of risk factors for torsade de pointes (including a family history of long QT syndrome or sudden cardiac death).
22. Known arrythmia
23. Liver function test results elevated more than 1.5-fold above the ULN for gamma glutamyl transferase, bilirubin (total, conjugated and unconjugated), ALP, AST or ALT. Volunteers with ALP and/or ALT/AST above the limits specified may be included, at the discretion of the Investigator, if the levels are unaccompanied by clinical signs and are determined to be normal variants.
24. Liver function test results elevated more than 1.5-fold above the ULN for gamma glutamyl transferase
25. Liver function test results elevated more than 1.5-fold above the ULN for bilirubin (total)
26. Liver function test results elevated more than 1.5-fold above the ULN for bilirubin (conjugated)
27. Liver function test results elevated more than 1.5-fold above the ULN for ALP. Volunteers with ALP above the limits specified may be included, at the discretion of the Investigator, if the levels are unaccompanied by clinical signs and are determined to be normal variants.
28. Liver function test results elevated more than 1.5-fold above the ULN for AST. Volunteers with AST above the limits specified may be included, at the discretion of the Investigator, if the levels are unaccompanied by clinical signs and are determined to be normal variants.
29. Liver function test results elevated more than 1.5-fold above the ULN for ALT. Volunteers with ALT above the limits specified may be included, at the discretion of the Investigator, if the levels are unaccompanied by clinical signs and are determined to be normal variants.
30. Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2) antibodies at the screening visit.
31. Positive test results for active hepatitis B surface antigen (HBsAg) antibodies at the screening visit.
32. Positive test results for active hepatitis C virus (HCV) antibodies at the screening visit.
33. Presence or having sequelae of known to interfere with the absorption, distribution, metabolism, or excretion of drugs such as gastrointestinal, liver, kidney, or other conditions .
34. Estimated creatinine clearance < 60 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.
35. History of substance abuse or alcohol abuse (defined as more than 10 standard drinks per week or regularly consuming more than 4 standard drinks on any one day; where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc./Vol], 100 mL wine [12% Alc./Vol], 30 mL spirit [40% Alc./Vol]) within 12 weeks prior to the screening visit.
36. Positive drugs of abuse at the screening visit.
37. Positive drugs of abuse at check-in (Day -1).
38. Positive alcohol breath test results at the screening visit.
39. Positive alcohol breath test results at check-in (Day -1).
40. Use of any prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days prior to the first study drug administration, - exceptions include use of contraceptives, occasional use of paracetamol (doses of 500 mg up to every 6 hours or 2 g per day maximum for no more than 3 consecutive days), ibuprofen (doses of 400 mg up to every 6 hours or 1.6 g per day maximum for no more than 3 consecutive days), topical ointments, and vitamins or dietary supplements.
41. Consumption of grapefruit or Seville orange (or products containing grapefruit or Seville orange) within 10 days prior to the first administration of study drug.
42. Demonstrated clinically significant (required intervention, e.g., emergency room visit, epinephrine administration) allergic reactions (e.g., food, drug, or atopic reactions, asthmatic episodes) which, in the opinion of the Investigator, would interfere with the volunteer's ability to participate in the trial.
43. Known hypersensitivity to any of the study drug ingredients.
44. Use of any vaccinations within 14 days prior to the first study drug administration.
45. For women of childbearing potential, a positive serum pregnancy test at the screening visit.
46. For women of childbearing potential, a positive urine pregnancy test (with confirmatory serum pregnancy test) at check-in (Day -1).
47. Females who are breastfeeding or planning to breast feed at any time during the study.
48. Donation of blood or plasma within 30 days prior to first study drug administration.
49. Loss of whole blood of more than 500 mL within 30 days prior to first study drug administration.
50. Receipt of a blood transfusion within 1 year of first study drug administration.
51. Participation in another clinical trial of an investigational drug within 60 days of the first study drug administration.

52. Any other condition or prior therapy that in the opinion of the Investigator would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.

    -

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PRV-002; PRV-002 active formulation	Drug: PRV-002; SAD portion: Eligible participants will be randomized to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomized to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.533 mg/kg (based on a 60kg participant) will be investigated. MAD portion: Eligible participants will be randomized to receive a multiple (one dose per day for 5 consecutive days). Dose escalation will be conducted in a total of 2 cohorts. Within each cohort, 6 participants will be randomized to receive of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.266 mg/kg (based on a 60kg participant) will be investigated.; Other Names: Experimental drug
Placebo Comparator: Placebo comparator; Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)	Drug: Placebo; Placebo used is hydroxypropyl beta cyclodextrin (HPβCD); Other Names: Placebo control

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety endpoint - Evaluation of the Incidence, severity, and relationship of AEs/SAEs (or ADEs/SADEs) (including withdrawals due to AEs (or ADEs)).	AEs/SAEs (or ADEs/SADEs) to be recorded as written descriptions on case report forms	Baseline pre-intervention (Day -28 to Day -2 and Day -1); during intervention and immediately afterwards (Day 1); Day 2; and through Day 5.
Safety endpoint - Change from baseline in physical examination findings (Full)	Full physical exam including general appearance, head, ears, eyes, nose and throat, neck (including thyroid and lymph nodes), respiratory system, cardiovascular system, gastrointestinal system, renal system, neurological condition, musculoskeletal system, skin and any other focused assessments suggested by the presence of specific symptoms and measured by written descriptions.	Baseline pre-intervention Day -28 to -2.
Safety endpoint - Change from baseline in physical examination findings (symptom directed)	Symptom-directed physical examination (focused assessments suggested by the presence of specific symptoms) will be performed if clinically indicated, as determined by the Investigator. The pre-dose physical examination assessment should be performed on the scheduled day, at any time prior to dosing. All other physical examinations will be performed within ± 1 hour of the nominated timepoint. Measured by written descriptions.	Baseline pre-intervention Day -1 and and Day 1; Day 2
Safety endpoint - Change from baseline in vital signs (including changes from baseline in SpO2).	SpO2 measured as percent of oxygen (%)	Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in vital signs (including changes from baseline in blood pressure).	Blood pressure measured for systolic and diastolic pressure as mm of mercury.	Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in vital signs (including changes from baseline in heart rate).	Heart rate measured as beats per minute (BPM)	Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in vital signs (including changes from baseline in respiration rate).	Respiration rate measured as breaths per minute	Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in vital signs (including changes from baseline in body temperature).	Body temperature measured as degrees Celsius (C)	Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.5hr, 1hr, 2hr, 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Changes from baseline in lung spirometry.	Lung spirometry measured as the ratio of forced expiratory value (FEV1)/ forced vital capacity (FVC) and reported as percentage (%)	Baseline pre-intervention between Day -28 to -2; Day 1 pre-intervention; Day 1 at 0.25hr, 1hr, 10hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in ECG parameters of heart rate	Heart ratel measured beats per minute (BPM)	Baseline pre-intervention; during intervention and immediately afterwards (Day 1); Day 2; and through Day 5.
Safety endpoint - Change from baseline in ECG parameters of PR interval, QRS interval, and QT interval	PR interval, QRS interval, and QT interval as measured in milliseconds (ms)	Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 pre-intervention; Day 1 at 0.5hr, 2hr, 6hr; 12hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in hematocrit values	Hematocrit measured as the percentage of red blood cells in whole blood (%)	Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in hemoglobin values	Hemoglobin measured as the amount of hemoglobin in whole blood measured as grams per deciliter (g/dL)	Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in Red Blood Cell (RBC) indices	RBC measured as the number of million RBCs per microliter (mcL) of blood	Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in Thrombocyte Count (Platelets); White Blood Cells (WBC); Basophils; Eosinophils; Lymphocytes; Monocytes; and Neutrophils.	Platelets measured as the number of cells per microliter (mcL) of blood	Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in the blood hormone level of Dehydroepiandrosterone-sulfate (DHEAS)	Dehydroepiandrosterone sulfate (DHEAS) measured as the number of micrograms per deciliter (µg/dL) of blood	Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5
Safety endpoint - Change from baseline in the blood hormone level of dihydrotestosterone (DHT)	Dihydrotestosterone (DHT) measured as the number of nano moles per liter (nmol/L) of blood	Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5
Safety endpoint - Change from baseline in the blood hormone level of luteinizing hormone (LH)	Luteinizing hormone (LH) measured as the number of International units per liter (IU/L)	Baseline pre-intervention Days -28 to -2
Safety endpoint - Change from baseline in the blood hormone level of dehydroepiandrosterone sulfate (DHEAS)	Dehydroepiandrosterone sulfate (DHEAS) measured as the number of micrograms per deciliter (mcg/dL)	Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5
Safety endpoint - Change from baseline in the blood hormone level of thyroid stimulating hormone (TSH)	Thyroid stimulating hormone (TSH) measured as the number of milli-international units per liter (mIU/L)	Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5
Safety endpoint - For postmenopausal women only, change from baseline in the blood hormone level of follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hGH)	Follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hGH) measured as the number of milli-international units per milliliter (mIU/mL)	Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5
Safety endpoint - Change from baseline in the blood hormone level of free thyroxine (FT4), testosterone, and dihydrotestosterone (DHT)	Free thyroxine (FT4), testosterone, and dihydrotestosterone (DHT) measured as the number of nanograms per deciliter (ng/dL)	Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5
Safety endpoint - Change from baseline in the blood hormone level of progesterone	Progesterone measured as the number of nanograms per miiliiliter (ng/mL)	Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5
Safety endpoint - Change from baseline in the blood hormone level of estradiol (E2) and free trilodothyronine (FT3)	Estradiol (E2) and free trilodothyronine (FT3) measured as the number of picograms per milliliter (pg/mL)	Baseline pre-intervention Day -1; Day 1 at 6hr; Day 2 at 24 hr; Day 5
Safety endpoint Change in baseline in clotting factors Partial thromboplastin time (aPTT) and Prothrombin time (PT)	Partial thromboplastin time (aPTT) and Prothrombin time (PT) measured as time to clot in seconds (sec)	Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in the clotting factor Fibrinogen	Fibrinogen measured as the number of milligrams per deciliter (mg/dL)	Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in the clotting factor International Normalized Ratio (INR)	International Normalized Ratio (INR) measured as the ratio of patient PT/control PT	Baseline pre-intervention between Day -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24 hr post intervention; Day 5
Safety endpoint - Change from baseline in urinalysis parameters bilirubin, blood, glucose, nitrites, protein, and urobilinogen	Bilirubin, blood, glucose, nitrites, protein, and urobilinogen measured as the number of milligrams per deciliter (mg/dL)	Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr
Safety endpoint - Change from baseline in urinalysis parameter ketones	Ketones measured as the number of millimoles per liter (mmol/L)	Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr
Safety endpoint - Change from baseline in urinalysis parameter leukocyte esterase	Leukocyte esterase measured as negative or positive; number of WBCs per high power field	Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr
Safety endpoint - Change from baseline in urinalysis parameter pH	pH measured as pH units	Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr
Safety endpoint - Change from baseline in urinalysis parameter specific gravity	Specific gravity measured as specific gravity units as a ratio of density of urine/density of water	Post dose Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24hr
Safety endpoint - Change from baseline in serum chemistry parameters globulin, protein, and albumin	Globulin, protein, and albumin measured as grams per deciliter (g/dL)	Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.
Safety endpoint - Change from baseline in serum chemistry parameter alkaline phosphatase	Alkaline phosphatase measured as International units per liter (IU/L)	Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.
Safety endpoint - Change from baseline in serum chemistry parameters bicarbonate, chloride, sodium, and magnesium	Bicarbonate, chloride, sodium, and magnesium measured as milliequivalents per liter (mEq/L)	Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.
Safety endpoint - Change from baseline in serum calcium, glucose, phosphate, creatinine, urea, uric acid, bilirubin (conjugated and unconjugated), high density lipoproteins, low density lipoproteins, total bilirubin, total cholesterol	Calcium, glucose, phosphate, creatinine, urea, uric acid, bilirubin (conjugated and unconjugated), high density lipoproteins, low density lipoproteins, total bilirubin, total cholesterol, triglycerides measured as milligrams per deciliter (mg/dL)	Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.
Safety endpoint - Change from baseline in serum chemistry parameters potassium	Potassium measured as millimoles per liter (mmol/L)	Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.
Safety endpoint - Change from baseline in serum chemistry parameters lipase, creatine kinase, lactate dehydrogenase, aspartate aminotransferase, gamma-glutamyl transferase, alanine aminotransferase, and amylase	Lipase, creatine kinase, lactate dehydrogenase, aspartate aminotransferase, gamma-glutamyl transferase, alanine aminotransferase, and amylase measured as Units per liter (U/L)	Baseline pre-intervention Days -28 to -2; Day -1; Day 1 at 6hr; Day 2 at 24hr; Day 5.
Safety endpoint - Change from baseline in virology parameters HIV-1/-2; HBsAg; HCV; SARS-COV-2	HIV-1/-2; HBsAg; HCV; SARS-COV-2 test results measured as negative or positive	Baseline pre-intervention Day -28 to -2
Safety endpoint - Change from baseline in drug screen findings for alcohol	Alcohol test results measured as percentage (%)	Baseline pre-intervention Day -28 to -2; Day -1
Safety endpoint - Change from baseline in urine drug screen findings for amphetamines, barbiturates, benzodiazepines, cocaine, cotinine, methamphetamines, opiates, phencyclidine, THC, and tricyclic antidepressants	Urine amphetamines, barbiturates, benzodiazepines, cocaine, cotinine, methamphetamines, opiates, phencyclidine, THC, and tricyclic antidepressants test results measured as nanograms per milliliter (ng/mL)	Baseline pre-intervention Day -28 to -2; Day -1
Safety endpoint - Change from baseline for pregnancy test for serum hCG and urine hCG	Serum hCG and Urine hCG levels measured in milli-international units per liter (mIU/L)	Serum pregnancy test Days -28 to -2 and on Day 5; Urine pregnancy test Day -1
Safety endpoint - Change from baseline for confirmation of postmenopausal status test for FSH	FSH levels measured in milli-international units per liter (mIU/L)	Baseline pre-intervention on Days -28 to -2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma pharmacokinetics - Cmax	Plasma PRV-002 Cmax measured as microgram per mL (mcg/mL)	Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.
Plasma pharmacokinetics - Tmax	Plasma PRV-002 time to Cmax	Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.
Plasma pharmacokinetics - area under the curve	Plasma PRV-002 Area under the concentration-time curve from 0 to time of last quantifiable concentration (AUC0-t) measured as min*kBq/mL	Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.
Plasma pharmacokinetics - area under the concentration-time curve	Plasma PRV-002 area under the concentration-time curve from 0 to infinity (AUC0-inf) measured as mg*h/L	Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.
Plasma pharmacokinetics - apparent terminal elimination half-life t1/2)	Plasma PRV-002 apparent terminal elimination half-life (t1/2) measured in minutes or hours	Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.
Plasma pharmacokinetics - terminal elimination rate constant (λz)	Plasma PRV-002 terminal elimination rate constant (λz) measured as elimination rate measured as constant K or Ke ((λz))	Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.
Plasma pharmacokinetics total apparent body clearance	Plasma PRV-002 total apparent body clearance measured as (CL/F)	Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.
Plasma pharmacokinetics - apparent volume of distribution	Plasma PRV-002 apparent volume of distribution measured as (Vz/F)	Samples collected on Day 1 pre-dose and at 0.25, 0.5, 1, 1.5, 2. 3, 4, 6, 10, 12hrs; Day 2 at 24 hr; Day 5.
Urine pharmacokinetics - cumulative amount of unchanged drug excreted in urine	Urine PRV-002 cumulative amount of unchanged drug excreted (Ae) in urine measured in micrograms per milliliter (mcg/mL)	Baseline pre-intervention on Day -1; Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24 hr.
Urine pharmacokinetics - renal clearance	Urine PRV-002 renal clearance measured as (CLr)	Baseline pre-intervention on Day -1; Day 1 at 0 to 6hr, 6 to 12hr, and 12 to 24 hr.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploratory endpoints - PRV-002 metabolites in plasma	PRV-002 metabolites in plasma measured as micrograms per milliliter (mcg/mL)	Samples collected on Day 1, 2, and 5
Nasal Spray Attributes Questionnaire	Nasal Spray Attributes Questionnaire score, based on a scale of 0 to 6, for each immediate attribute assessed.	Nasal spray attributes questionare completed on Day 1 at 15 minutes post dose

Collaborators and Investigators

• Sponsor: Odyssey Group International, Inc.
• Collaborators: Avance Clinical Pty Ltd.
• Investigators: Principal Investigator: Philip Ryan, Dr., Nucleus Network

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (Actual): February 9, 2022
• Primary Completion (Actual): October 1, 2022
• Study Completion (Actual): September 13, 2024

Study Registration Dates

• First Submitted: August 12, 2021
• First Submitted That Met QC Criteria: August 27, 2021
• First Posted (Actual): September 2, 2021

Study Record Updates

• Last Update Posted (Estimated): November 4, 2024
• Last Update Submitted That Met QC Criteria: October 31, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: Safety; Pharmacokinetics; Tolerability; PRV-002
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Wounds and Injuries; Craniocerebral Trauma; Trauma, Nervous System; Brain Injuries, Traumatic; Brain Injuries
• Other Study ID Numbers: PRV-002-AU-01; PRV-002-AUU-01 (Other Identifier: Avance)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes